ClinicalTrials.gg
RecruitingNCT07021742Updated Nov 18, 2026

BioHealx® Anal Fistula Device Post Market Surveillance Study

An observational study in Fistula-in-ano, sponsored by Signum Surgical USA Inc.. Recruiting at 6 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Signum Surgical USA Inc. · Observational

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Nov 18, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Rectal Fistula with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Rectal Fistula · United States.

Started
2025
with 2 others
Observational
5 of 20
3 open now
Registered
18th of 20
by date
Lead sponsor
1 of 20
Signum Surgical USA Inc.

Among the 20 studies in Rectal Fistula with a site in United States, this one is one of 3 that started in 2025, is one of 5 observational ones, and was the 18th registered.

Rectal Fistula

170 studies on the registry are indexed under Rectal Fistula; 45 are open to participants now.

Browse Rectal Fistula studies →

Open to participants now

7 of the 20 studies in Rectal Fistula with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Rectal Fistula studies recruiting now, 18 (69%) set no upper age limit and 7 (27%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Rectal Fistula with a site in United States, or all of them as a file.
02

Study summary

This post market surveillance study is a single arm multicenter study to demonstrate the long-term durability and effectiveness of the BioHealx Anal Fistula Device for fistula-in-ano closure (internal and external fistula openings).

03

Conditions studied

  • Fistula-in-ano

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients presenting for treatment of mature, cryptogenic, transsphincteric, non-branching fistulas in ano via tissue apposition.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 - 75 years
  • Presence of Single Continuous Anal Fistula presenting for initial curative surgery
  • Failed or Recurrent Anal Fistula Closure
  • Minimum of 6-weeks of draining seton placed prior to procedure.
  • Availability for follow-up contacts and willingness to complete the .

Exclusion criteria

Exclusion Criteria:

  • Fistula tract shorter than 2cm
  • Complex fistula tract (branching)
  • > 35
  • Known uncontrolled diabetes or other systemic condition associated with impaired healing
  • Known -positive or
  • Rectal prolapse
  • Pregnancy
  • Rectal / fistula
  • Crohn's disease
  • Ulcerative proctitis
  • Hidradenitis suppurativa of the anal region
  • Pilonidal sinus disease
  • Presence of hemorrhoid Involving fistula site
  • Continuous use of anti-inflammatory
  • Intersphincteric fistula in ano or fistula treatable by simple fistulotomy
  • Active infection or abscess involving fistula site
  • Known allergy to PLGA material
  • Any severe acute or uncontrolled chronic disease that according to the investigator might render the patient unsuitable for the study
  • Treatment with an drug or medical device in the past 30 days
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
36 Months
Patient registry
Yes

Groups and cohorts

  • BioHealx

    Subjects will have their anal fistula treated with the BioHealx Anal Fistula Device.

    Device: BioHealx

Interventions

  • DeviceBioHealx

    Subjects will have their anal fistula treated with the BioHealx Anal Fistula Device, a bioabsorbable implant designed to securely close the fistula internal opening, preventing reinfection, while allowing for drainage through the external opening during healing.

06

What researchers measure

Primary outcomes

  1. Successful Closure Repair

    Successful closure repair of the anal fistula as determined by complete healing, i.e., internal and external opening closed (no evidence of an external opening present) without drainage

    Time frame: 12 Months

  2. Non-Recurrence Incidence

    Non-recurrence incidence determined by continued closure of the external fistula opening.

    Time frame: 24 and 36 Months

Secondary outcomes

  1. Fecal Incontinence Quality of Life

    Fecal incontinence Quality of Life (FIQL) score at each follow-up visit (baseline visit and from 6-month and at subsequent follow-up visit) The FIQL score includes 29 items which form four scales: lifestyle, coping/behavior, depression/self-perception, and embarrassment. The FIQL scale range includes a range of response options across its items, from 1 to 4 for most items, 1 to 5 for one item, and 1 to 6 for another. Lower scores indicate lower quality of life.

    Time frame: 6 Months, 9 Months, 12 Months, 24 Months, 36 Months

  2. Fecal Incontinence Severity Index (FISI)

    Fecal Incontinence Severity Index (FISI) at each follow-up visit (baseline visit and from 6-month and at each subsequent follow-up visit). The Fecal Incontinence Severity Index (FISI) Scale typically ranges from 0 to a maximum value 61. Higher scores on the FISI scale indicate a worse outcome, reflecting greater severity of fecal incontinence symptoms.

    Time frame: 6 Month, 9 Month, 12 Month, 24 Month, 36 Month

  3. Health Related Quality of Life

    SF-36 Quality of life data will be collected (baseline visit and from 6-month and at each subsequent follow-up visit). Short Form 36 (SF-36) is a generic self-reported outcome measure that quantifies the quality of life in relation to health status. It is a 36-item valid and reliable evaluation with eight areas covering physical functioning, role limitations brought on by physical issues, bodily pain, general health perceptions, vitality, social functioning, role limitations brought on by emotional issues, and perceived mental health. The SF-36 also contains a single question called "health transition" that measures how respondents feel their over health status has changed over the course of a year. The scores range from 0-100 (the worst possible to the most possible)

    Time frame: 6 Months, 9 Months, 12 Months, 24 Months, 36 Months

  4. Pain Score

    Wong-Baker FACES Pain scores will be recorded at each follow-up visit (baseline visit and from 6-month and at each subsequent follow-up visit). The FACES Pain Scale ranges from 0 (no pain) to 10 (the worst pain).

    Time frame: 6 Months, 9 Months, 12 Months, 24 Months, 36 Months

  5. Rescue Analgesic and Therapeutic Antibiotic Use

    Occurrence of use of rescue analgesic and/or therapeutic antibiotics beyond post-operative Day 5 after the surgery and at each follow-up visit.

    Time frame: 6 Weeks, 3 Months, 6 Months, 9 Months, 12 Months, 24 Months, 36 Months

Other outcomes

  1. Device and Procedure Related Adverse Events

    Measurement of device and/or procedure related adverse events will be recorded.

    Time frame: 6 Weeks, 3 Months, 6 Months, 9 Months, 12 Months, 24 Months, 36 Months

  2. Adverse Event Comparison

    Measurement of, incidence, severity and persistence of device and/or procedure related adverse events will be recorded and compared with previous BioHealx Anal Fistula Device clinical results and relevant comparator devices (e.g. cutting seton) and procedures (e.g., LIFT).

    Time frame: 6 Weeks, 3 Months, 6 Months, 9 Months, 12 Months, 24 Months, 36 Months

  3. Occurrence of Fecal Incontinence

    Fecal continence will be measured through combination of the patient reported Fecal Incontinence Quality of Life questionnaire (FIQL) and the Fecal Incontinence Severity Index questionnaire (FISI) scores at baseline and subsequent periods. Fecal incontinence Quality of Life (FIQL) score at each follow-up visit (baseline visit and from 6-month and at subsequent follow-up visit) The FIQL score includes 29 items which form four scales: lifestyle, coping/behavior, depression/self-perception, and embarrassment. The FIQL scale range includes a range of response options across its items, from 1 to 4 for most items, 1 to 5 for one item, and 1 to 6 for another. Lower scores indicate lower quality of life. The Fecal Incontinence Severity Index (FISI) Scale typically ranges from 0 to a maximum value 61. Higher scores on the FISI scale indicate a worse outcome, reflecting greater severity of fecal incontinence symptoms.

    Time frame: Baseline, 6 Weeks, 3 Months, 6 Months, 9 Months, 12 Months, 24 Months, 36 Months

  4. Rescue Analgesic and Therapeutic Antibiotic Comparison

    Rescue analgesic and therapeutic antibiotic use will be recorded and compared with previous BioHealx Anal Fistula Device clinical results and other relevant fistula treatments.

    Time frame: 6 Weeks, 3 Months, 6 Months, 9 Months, 12 Months, 24 Months, 36 Months

07

Study locations

6 of 6 sites recruiting
  • The Colorectal Institute
    Fort Myers, Florida 33912, United States
    Recruiting
    • J Neale, MD · Contact
    • J Neale, MD · Principal investigator
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
    Recruiting
  • Weill Cornell Medicine
    New York, New York 10021, United States
    Recruiting
    • KM Muktasid · Contactkmm4010@med.cornell.edu · 646-962-2270
    • Lea Lowenfeld, MD, FACS, FASCRS · Principal investigator
  • Northwell Health
    Staten Island, New York 10305, United States
    Recruiting
  • Maininle Health Lankenau
    Bryn Mawr, Pennsylvania 19010, United States
    Recruiting
    • Mainline Health Lankenau · ContactHandforthK@mlhs.org · 484-476-1000
    • P Pearson, MD · Principal investigator
  • Geisinger
    Danville, Pennsylvania 17822, United States
    Recruiting
    • K Rebuck · Contactkrebuck@geisinger.edu · 570-271-6856
    • Christopher Buzas, DO · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jun 2025 (actual). Primary completion is estimated for Feb 2027, 20 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Oct 2026 → Feb 2027 and completion Dec 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2025
First posted
Jun 15, 2025
StartActual
Jun 14, 2025
Primary completionEst.
Feb 2027was Oct 2026
CompletionEst.
Mar 2027was Dec 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Feb 2027
Nov 18, 2026
Study completion
Dec 2026→Mar 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Primary completion Oct 2026→Feb 2027
    Study completion Dec 2026→Mar 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07021742
Lead sponsor
Signum Surgical USA Inc.
Responsible party
Sponsor
First posted
Jun 15, 2025
Start date
Jun 14, 2025
Primary completion
Feb 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Katy Feeny
Contact
kjclinconsulting@gmail.com
610-860-6577

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion